Author

Eric Joseph Avery

Observed names: E. Avery, E.J. Avery, ERIC J AVERY, Eric Avery, Eric J Avery, Eric J. Avery

Observed institutions: Nebraska Hematology-Oncology, University of Nebraska Medical Center

ORCID: 0000-0002-0480-0721

Observed ORCID: 0000-0002-0480-0721

OpenAlex ID: A5073166113

ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia

2020 · Paolo Ghia, Andrzej Pluta, et al. · Journal of Clinical Oncology · 382

Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 Study

2024 · Luis G. Paz-Ares, Oscar Juan-Vidal, et al. · Journal of Clinical Oncology · 151

PDF

Acalabrutinib Versus Investigator’s Choice in Relapsed/Refractory Chronic Lymphocytic Leukemia: Final ASCEND Trial Results

2022 · Paolo Ghia, Andrzej Pluta, et al. · HemaSphere · 117

Transgender Health and HIV Prevention: Needs Assessment Studies from Transgender Communities Across the United States

2006 · Walter O. Bockting, Eric J. Avery · 44

Acalabrutinib vs Rituximab Plus Idelalisib (IdR) or Bendamustine (BR) by Investigator Choice in Relapsed/Refractory (RR) Chronic Lymphocytic Leukemia: Phase 3 ASCEND Study

2019 · P. Ghia, A. Pluta, et al. · Hematological Oncology · 27

Therapeutic options for elderly patients with advanced non-small cell lung cancer

2009 · Eric J. Avery, Anne Kessinger, et al. · Cancer Treatment Reviews · 22

Three-Year Follow-up of the Ascend Trial: Acalabrutinib Vs Rituximab Plus Idelalisib or Bendamustine in Relapsed/Refractory Chronic Lymphocytic Leukemia

2021 · Wojciech Jurczak, Andrzej Pluta, et al. · Blood · 21

1379P Margetuximab (M) with retifanlimab (R) in HER2+, PD-L1+ 1st-line unresectable/metastatic gastroesophageal adenocarcinoma (GEA): MAHOGANY cohort A

2021 · D.V. Catenacci, H. Park, et al. · Annals of Oncology · 14

Breast Cancer Subtype Influences the Accuracy of Predicting Pathologic Response by Imaging and Clinical Breast Exam After Neoadjuvant Chemotherapy

2016 · ASHLEY R WALDREP, ERIC J AVERY, et al. · Anticancer Research · 10

PDF

Thrombotic thrombocytopenic purpura masquerading as preclampsia with severe features at 13 weeks' gestation

2020 · Eric J. Avery, Sean P. Kenney, et al. · American Journal of Hematology · 7

PDF

Acalabrutinib (Acala) versus idelalisib plus rituximab (IdR) or bendamustine plus rituximab (BR) in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): ASCEND final results.

2020 · Paolo Ghia, Andrzej Pluta, et al. · Journal of Clinical Oncology · 7

Ascend Phase 3 Study of Acalabrutinib vs Investigator's Choice of Rituximab Plus Idelalisib (IDR) or Bendamustine (BR) in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)

2020 · Holger Hebart, Paolo Ghia, et al. · 6

Acalabrutinib versus rituximab plus idelalisib or bendamustine in relapsed/refractory chronic lymphocytic leukemia: ASCEND results at 4 years of follow-up.

2022 · Wojciech Jurczak, Andrzej Pluta, et al. · Journal of Clinical Oncology · 5

Introduction

2005 · Walter Bockting, Eric Avery · International Journal of Transgenderism · 3

Acalabrutinib vs Rituximab Plus Idelalisib (IdR) or Bendamustine (BR) by Investigator Choice in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia: Phase 3 ASCEND Study

2019 · Paolo Ghia, Andrzej Pluta, et al. · Clinical Lymphoma Myeloma & Leukemia · 2

Acalabrutinib versus Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory CLL: The Randomised, Controlled, Phase 3 ASCEND Trial

2019 · Paolo Ghia, Andrzej Pluta, et al. · SSRN Electronic Journal · 2

P668: Acalabrutinib Vs Rituximab Plus Idelalisib or Bendamustine in Relapsed/refractory Chronic Lymphocytic Leukemia: Ascend Results at ~4 Years of Follow-up

2022 · P. Ghia, A. Pluta, et al. · HemaSphere · 1

Lymphomatoid papulosis in a patient treated with glatiramer acetate and the glatiramoid Glatopa for multiple sclerosis: A case report

2021 · Afsaneh Shirani, Scott R Dalton, et al. · Journal of Central Nervous System Disease · 1

PDF

CLL-091: Acalabrutinib Versus Idelalisib Plus Rituximab (IdR) or Bendamustine Plus Rituximab (BR) in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): ASCEND Final Results

2020 · Paolo Ghia, Andrzej Pluta, et al. · Clinical Lymphoma Myeloma & Leukemia · 1

Works count: 19

Citation count: 823

H-index: 9

I10-index: 9